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Cerebral dopamine neurotrophic factor (CDNF) and mes-
encephalic astrocyte-derived neurotrophic factor (MANF) 
are proteins that have received increasing attention in the 
last decades. Although they are called neurotrophic factors 
they are drastically different from neurotrophic factors in 
their expression and physiological actions. They are located 
in the lumen of the endoplasmic reticulum (ER) and their 
basal secretion from neurons is very low. However their se-
cretion is stimulated upon ER calcium depletion by chemi-
cal probes such as thapsigargin, a sarco/endoplasmic re-
ticulum Ca2+-ATPase (SERCA) pump inhibitor. Exogenous 
MANF and CDNF possess therapeutic properties in sev-
eral neurological disease models, including Parkinson dis-
ease and stroke. Endogenous MANF expression has been 
shown to be neuroprotective, as well as administration of 
either CDNF or MANF into the extracellular space. In this 
review, we focus on their therapeutic effects, regulation of 
expression and secretion, comparison of their mechanisms 
of action, and their application to the brain parenchyma as 
recombinant proteins.
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The molecular characterization and protective effects of 
mesencephalic astrocyte-derived neurotrophic factor 
(MANF) were first described by Petrova et al (1). The protein 
was initially characterized from a mesencephalic type-1 
astrocyte cell line followed by cloning of MANF from hu-
man cDNA. MANF was found to be neuroprotective at ng/
mL concentrations on dopaminergic neurons in vitro, the 
results that are difficult to interpret due to the fact that a 
transmembrane receptor is not identified, as will be dis-
cussed below. Our later studies have found that particu-
larly in vivo, MANF is neuroprotective when administered 
as a recombinant protein or delivered via adeno-associat-
ed virus (AAV). In vitro, we have shown that endogenous 
MANF is neuroprotective against oxygen-glucose depriva-
tion, when expressed in cells, and when it is localized in the 
endoplasmic reticulum (ER). However, the neuroprotective 
effects of recombinant protein added to the culture me-
dium have been variable.
Cerebral dopamine neurotrophic factor (CDNF) was found 
by using a bioinformatics screen in order to identify pro-
teins with conserved cysteines (2). It was found that CDNF 
and MANF show homology, and they form a family of pro-
teins with two isoforms in vertebrates and only one iso-
form in invertebrates. The homology of human CDNF ami-
no acid identity to human MANF is 59%, and 49% and 46% 
to D. melanogaster and C. elegans MANF proteins, respec-
tively (2). It was further found that in cultured HEK-293 cells 
CDNF is secreted after transient transfections. However, 
the secretion of CDNF from neurons is not as trivial. As dis-
cussed below, CDNF was found to be neuroprotective in 
vivo, and found not to have drastic survival-promoting ef-
fects when added to the culture medium in vitro (2).
Since their discovery, the number of publications with 
these proteins has increased over the years (Figure 1). 
There has been great interest due to their success in animal 
models of Parkinson’s disease and stroke (2,3); and CDNF is 
currently in clinical trials for Parkinson’s disease. Their prop-
erties differ from other neurotrophic factors due to their 
structure where the N-terminal domain is a saposin-like 
domain, which is known to interact with lipids, and the C-
terminal with its single cysteine bridge and KDEL receptor 
retention sequence at its end (4). How the structural prop-
erties of MANF and CDNF affect their functions, as well as 
their effects in models of disease and injury, is discussed in 
greater detail below.
A SYSTEMATIC LITERATURE REVIEW OF MANF AND 
CDNF
The date up to which publications on MANF and CDNF 
were accessed was March 11, 2019. A search of NCBI’s 
PubMed with the terms “MANF”, “mesencephalic astro-
cyte-derived neurotrophic factor”, or “Armetl1”, as well as 
a search using “CDNF”, “cerebral dopamine neurotrophic 
FIgURE 1. The number of publications on MANF and CDNF since the first paper describing their molecular characterization and 
therapeutic effects. Source Scopus, March 11, 2019. MANF was searched with keywords Armetl1 OR MANF OR mesencephalic 
astrocyte-derived neurotrophic factor in the title, abstract, and keywords. CDNF was searched with Armetl1 OR CDNF or cerebral 
dopamine neurotrophic factor in the title, abstract, and keywords.
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factor”, or “Armetl1”, (Figure 1) was performed. The au-
thors used an unbiased approach to select the publica-
tions, and therefore publications from various laboratories 
and related to different aspects of the factors were used. 
Publications indexed in PubMed were chosen since this 
is considered a reliable and comprehensive resource for 
searching biomedical literature (5). Though the authors 
tried to avoid “cherry picking” (6) of published journal ar-
ticles, it should be noted that the focus of the review was 
the therapeutic potential of the neurotrophic factors and, 
therefore, to the best of their ability, all relevant articles 
are mentioned and referenced. Additionally, the authors 
aimed to provide a critical appraisal of the literature, also 
in an unbiased manner.
ThERApEUTIC EFFECTS IN pARKINSON’S DISEASE
Neurotrophic factors have shown to be both neuroprotec-
tive and neurorestorative in animal models of Parkinson’s 
disease (7). The concept of neurorestoration has been re-
viewed recently (7), but briefly, it is based on animal and 
human studies that indicated that at the onset of symp-
toms, although most striatal dopamine terminals are de-
generated, most of the dopaminergic neurons in the 
substantia nigra pars compacta are still present (8). Further-
more, it has been indicated that when dopamine neurons 
die they first lose their dopamine phenotype and become 
metabolically inactive skeletons, enabling neurorestorative 
therapies to restore the neurotransmitter phenotype and 
metabolic activity.
Both MANF and CDNF have mainly been used in models of 
Parkinson’s disease. While MANF has been effective in cells 
and some animal models, CDNF has shown efficacy in ro-
dent models of the disease, and CDNF is currently in Phase 
I/II clinical trials for Parkinson disease (9).
MANF has shown positive effects in in vitro models using 
6-hydroxydopamine (6-OHDA), a toxin used to selective-
ly destroy catecholaminergic neurons. Although these are 
not the neurons specifically affected in Parkinson’s disease 
patients, they are used to model Parkinson’s disease in cells 
and animals. It was found that MANF protected against 
cell death in neuronal cell culture (10,11) However, a study 
in C. elegans demonstrated that the MANF homologue in 
worms was important for dopamine neurons (12). The re-
sults showed that significantly more dopamine neurons 
were lost over time in the MANF mutants compared to 
wild-type controls, which was accompanied by ER stress 
and behavioral deficits. Also, co-expressing MANF and 
α-synuclein in C. elegans protected dopamine neurons, af-
fected behavior, and reduced aggregation of α-synuclein. 
MANF has also been used in rat models of Parkinson’s dis-
ease. When MANF was delivered as a recombinant pro-
tein or using AAV unilaterally to the striatum of rats after 
6-OHDA, it restored the dopaminergic system, more spe-
cifically tyrosine hydroxylase (TH) fibers in the striatum and 
TH+ cells in the substantia nigra pars compacta, as well as 
rotational behavior (13,14). To complement this, MANF in-
creased stimulus-evoked release of dopamine as well as 
dopamine turnover in freely moving rats (15). In midbrain 
slices it potentiated inhibitory GABA current in dopamine 
neurons (16), demonstrating that MANF has some specif-
ic effects on the dopaminergic system. In addition to the 
AAV-MANF results in 6-OHDA, another study used lentivi-
rus (LV)-MANF, LV-CDNF, as well as a combined vector in 
the same toxin model. The LV-MANF injection to the sub-
stantia nigra had a protective effect on the cells there, and 
LV-CDNF had a protective effect on the TH+ fibers of the 
striatum after nigral injection (17). Interestingly, the com-
bined vector was the most effective. However, these find-
ings have to be cautiously interpreted due to the lack of 
expression data and the composition of the vector, thus 
making it difficult to know the exact localization of these 
proteins in the brain.
CDNF has been studied extensively for Parkinson’s disease 
since the initial study showed it to be neuroprotective in a 
6-OHDA model (2). CDNF was also tested using a mouse 
model treated with toxin MPTP (1-methyl-4-phenyl-1,2,5,6-
tetrahydropyridine), a neurotoxin that has been shown to 
result in parkinsonism in humans (18). When CDNF was 
given bilaterally to the striatum before or after the MPTP, 
the mice showed improved locomotor activity, as well as 
protection of TH fibers in the striatum and TH+ cells in the 
substantia nigra pars compacta (19). This indicated that 
CDNF could have a protective effect in toxin models of Par-
kinson’s disease. Around the same time, another 6-OHDA 
experiment was performed, in which CDNF was given con-
tinuously to the striatum – this also improved rotational 
behavior, and protection of TH in the striatum and substan-
tia nigra (20). A combination experiment using CDNF and 
glial cell-derived neurotrophic factor (GDNF) in a 6-OHDA 
model has been recently performed. However, at the low 
doses of CDNF used, there was no significant effect on 
behavior or TH compared to vehicle, although there was 
indication that CDNF was acting via an ER stress-related 
mechanism (21). An interesting study used both CDNF 
alone or in combination with deep brain stimulation 
after a 6-OHDA lesion of the medial forebrain bun-
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dle, a lesion that can be considered severe. When CDNF 
was injected to the substantia nigra four weeks after the 
lesion, but not one week, it affected rotational behavior 
(22). Additionally, when nigral CDNF was combined with 
deep brain stimulation of the subthalamic nucleus, it af-
fected behavior. It is clear from these studies that CDNF is 
effective in some cases but not in others. Dose, injection 
location, lesion paradigm, and single vs chronic infusion, 
are all important aspects for CDNF to exert its neurotrophic 
effects in the brain.
In addition to CDNF protein alone, a few studies have used 
AAV-CDNF in a 6-OHDA model of Parkinson’s disease in rats. 
AAV2-CDNF administered two weeks before the 6-OHDA 
toxin improved the rotational behavior, but showed a less 
robust effect on TH fibers and cells, and only at the highest 
virus titer (23). This could be due to the spreading of the 
protein since there was minimal coverage of the striatum 
in comparison with the protein without viral vector (20,24). 
Other studies have shown positive results with AAV-CDNF: 
both AAV2-CDNF (25) and AAV8-CDNF (26) showed posi-
tive effects, but the latter was a much milder lesion than in 
the previous studies.
CDNF was also shown to reduce the number of activated 
glial cells in the nigra of rats that received a CDNF plasmid 
carried by a neurotensin-polyplex after a 6-OHDA lesion of 
the striatum (27). Additionally, CDNF was tested in mon-
keys and showed an increase in striatal DAT activity after a 
6-OHDA lesion (28).
Importantly, a study using cell culture and a large amount 
of CDNF showed that it was able to protect against 
α-synuclein preformed fibril-induced cell death (29). This is 
in accordance with the abovementioned data on MANF.
Future directions
Both MANF and CDNF have positive effects on models of 
Parkinson’s disease, however, to determine whether this 
is through an ER-related mechanism needs further study. 
Since the clinical trials with neurotrophic factors have 
shown conflicting results (7,30-32), it remains to be seen 
whether neurorestorative therapy is feasible. The chal-
lenge is that when the disease is diagnosed most of the 
dopaminergic axons are degenerated, and this seems to 
be progressing rather fast (33). Nevertheless, what makes 
MANF and CDNF interesting and distinct from other neu-
rotrophic factors is that intracellular MANF mediates 
protein homeostasis, but whether this is also the 
case for extracellularly applied proteins is not yet known. 
However, currently only CDNF is at the trial stage and only 
for Parkinson’s disease (34). To make the therapies more ef-
fective, one option is to start the neuroprotective therapies 
earlier. However, for this to be possible we critically need 
quantitative measures for the disease progression since 
the Parkinson’s disease rating scale is mostly descriptive 
and positron emission tomography (PET) ligand studies for 
dopamine transporter (DAT) are expensive and not avail-
able to all. Also, the development of novel drug therapies 
is most often a linear process where the diagnosis of the 
disease is not currently connected with it in the best pos-
sible way. By combining reporter assays for studying basic 
biological processes to studies finding biological reporters 
and disease biomarkers, we can make the drug develop-
ment not only more rational but also more interconnected 
with clinically measurable outcomes. These issues are nat-
urally not specific to Parkinson’s disease but present a huge 
challenge in all neurological diseases.
EFFECTS IN OThER NEURODEgENERATIVE DISEASES
MANF and CDNF have been tested successfully in other 
models of neurodegenerative diseases. Interestingly, most 
of the protection seen may be occurring through an apop-
totic or inflammatory-related mechanism, rather than the 
one involving the ER specifically.
MANF is expressed in the human retina and optic nerve 
(35), and it protects retinal ganglia cells from hypoxia and 
apoptotic injury in vitro and in vivo (36). MANF in D. mel-
anogaster (DmMANF) was also found to be expressed in 
the fly visual system neurons and glia, and its removal 
caused degeneration of glial cells (37). MANF was shown 
to decrease apoptosis and ameliorate traumatic spinal 
cord injury in mice (38). Additionally, it was up-regulated 
in human samples of traumatic brain injury and reduced 
neuroinflammation in a rat model (39). Interestingly, CDNF 
was also shown to have a positive effect on spinal cord 
injury. CDNF was given via bone marrow-derived mesen-
chymal stem cells in a spinal cord injury model in rats: it 
had an anti-inflammatory effect, where it protected the 
cells from injury, and improved locomotor behavior (40). 
Clearly MANF, as well as CDNF, have some anti-apoptot-
ic and/or anti-inflammatory effects in models that utilize 
mechanical damage, and MANF is a potential target for 
retinal diseases.
In addition to these models, both MANF and CDNF have 
had clear effects in models of Alzheimer’s disease. In cells 
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and a transgenic Alzheimer’s model, MANF was able to 
protect against cell death caused by amyloid-β, possibly 
through an ER stress-related mechanism (41). Related to 
this, CDNF was able to enhance long-term memory in both 
wild-type and Alzheimer’s transgenic mice (42). However, 
this study had different outcome measures than the MANF 
study, and CDNF was not able to increase neurogenesis or 
decrease amyloid-β build-up.
Future directions
MANF’s and CDNF’s effects on these models are intrigu-
ing and we have some evidence of how they may be oc-
curring. MANF’s role in diabetes has been established us-
ing the knockout model (43,44) as well as in patients (45). 
However, further testing in retinal disease and traumatic 
injury is needed to understand the mechanisms of MANF’s 
action as well as its potential therapeutic effects. All of 
these lines of study may be important for future disease 
therapies, though in particular these proteins’ effects on 
both α-synuclein and amyloid-β point to potential use in 
neurodegenerative disease therapy, a strong unmet need 
in medicine. As above with Parkinson’s disease, more ac-
curate and earlier diagnostics for synucleinopathies and 
Alzheimer’s disease are needed for neurotrophic factor 
therapy so that neuronal projections can be restored be-
fore they die. And if these factors can affect abnormal pro-
tein build-up in disease, this would be a potentially useful 
target. However, antibodies to amyloid-β have not fared 
well in clinical trials (46,47), and it is not fully clear how 
the aggregation of protein affects disease progression. Al-
though if MANF and CDNF can moderate effects through 
an anti-inflammatory, ER stress, and/or apoptotic mecha-
nism, this may be more useful for protection than simply 
aiming to rid the brain of these proteins, particularly if the 
build-up is in fact a protective mechanism itself. Results 
from the current clinical trial with CDNF in Parkinson’s dis-
ease may provide more information for future potential 
therapies.
EFFECTS OF MANF AND CDNF IN STROKE
Our previous studies have shown that both recombinant 
MANF protein and overexpression via AAV vector are neu-
roprotective when they are applied before cortical isch-
emia reperfusion injury (3,48). In both cases, the neuropro-
tection was observed with hastened behavioral recovery 
over the two-week time period after stroke, indicating not 
only neuroprotection, but also that MANF has beneficial 
effects post-stroke. In addition, we found that MANF pre-
vented the apoptosis measured as TUNEL (terminal de-
oxynucleotidyl transferase (TdT) dUTP Nick-End Labeling) 
staining when protein was applied directly to the rat brain 
before distal middle cerebral artery occlusion (3). These 
results were furthered by our studies in which we admin-
istered MANF post-stroke after the lesion had fully devel-
oped to study how MANF affects brain repair processes. 
When MANF was applied via intracerebroventricular injec-
tions or infusion, we found that it did not affect the prolif-
eration of neuronal stem cells, but increased the number 
of neuronal precursors in the areas close to the ischemic 
lesion (49). These studies also indicated that MANF acts by 
modulation of proteins of the cell cytoskeleton and initi-
ates an intracellular signaling cascade related to the in-
flammatory pathways. We found that MANF increased the 
levels of phosphorylated signal transducer and activator of 
transcription 3 (STAT3) and particularly serine 727 and ty-
rosine 705, and that it increased levels of glial-associated 
intermediate filament (GFAP) in neuronal stem cells (49). 
Another study in which we used the peri-infarct target-
ing methods we established (50) showed that post-stroke 
treatments facilitate functional recovery after stroke. Fur-
thermore, unbiased RNA screening showed that MANF 
treatment increased the levels of phagocyte markers, in-
dicating that MANF hastens clearance of cell debris af-
ter stroke (51). Taken together, these studies indicate that 
MANF promotes brain recovery after stroke via a mecha-
nism that has both immunomodulatory and neuroregen-
erative effects in the stroke brain.
The above-mentioned studies were conducted in parallel 
with the studies on development of the cortex in MANF 
knockout mice. The studies on cortex development are 
relevant to discuss here since many cellular processes are 
similar in development and after ischemic insult in adult 
brain (eg, activation of glial cells and neurogenesis). In 
these studies, we found that the developing neurons had 
shorter neurite extensions as well as slower migration of 
neurons (52) that correlated with an increase in markers 
of the unfolded protein response (UPR). Particularly, it is in-
teresting that spliced Xbp1 was increased indicating that 
activation of the IRE1 pathway of the UPR results in shorter 
neurite extension and slower cortex development (52). In-
terestingly, recent studies on the UPR and cortex develop-
ment indicated that constitutive PERK activity caused inhi-
bition on indirect neurogenesis and smaller cortices (53). 
Their follow-up study indicated that this can mediate the 
phenotype of Zika virus infection-caused alterations in 
brain development (54). Thus, it can be concluded that 
activation of UPR pathways and chronic ER stress 
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can regulate direction of neurogenesis as well as the dy-
namics of neurodevelopment.
Future directions
The questions that remain for future studies are for exam-
ple, how does MANF modulate the inflammatory cells and 
which inflammatory cells are involved? Does it affect pri-
marily microglia post-stroke or macrophages, or does it af-
fect other infiltrating immune cells? How does MANF af-
fect the number of phagocytes, and, since they are motile 
cells, does MANF affect their migration similarly as we ob-
served for developing neurons? In terms of ER stress and 
different UPR pathways, it is important to study how differ-
ent pathways affect the changes in neurogenesis and mat-
uration of cells into specific neuronal phenotypes. This can 
also be extended into regeneration of the adult nervous 
system using in vivo reprogramming as well as transplanta-
tion studies with neuroprogenitor cells.
EFFECTS OF EXTRACELLULARLY AppLIED VS 
ENDOgENOUS pROTEIN
Both MANF and CDNF can function differently depending 
on whether the role of endogenous protein is measured 
or whether the proteins are given exogenously to cells 
or tissue. As expressed proteins, they are localized at the 
ER lumen and have only minimal secretion from neurons, 
even after lentiviral overexpression (55). However, it should 
be noted that a proportion of intracellular and extracellu-
lar MANF or CDNF is likely different in non-neuronal cells 
and needs to be studied separately on each cell type. They 
both have N-terminal signal sequences, similar to classi-
cal neurotrophic factors, which target them to secretion. 
However, at the C-terminus they have a KDEL retention 
sequence that retains them from Golgi to the ER lumen 
(56). Moreover, for MANF it has been shown that the re-
moval of the last seven amino acids, ASARTDL, the reten-
tion sequence, causes them to be secreted from neuronal 
cells (56). However, caution should be used for C-terminal 
tags since they can interfere with the native expression in 
the ER. In the lumen, MANF interacts with GRP78 (aka BiP, 
binding immunoglobulin protein) (57) and it has been re-
cently shown that MANF is involved in the folding of high 
molecular weight proteins together with GRP78 (58). It 
was indicated that MANF inhibits ADP release from GRP78 
and ATP binding to GRP78, and thereby modulates pro-
tein folding in the ER lumen via GRP78. Our result indi-
cates that the CXXC domain at the C-terminus is im-
portant for the neuroprotective effect of expressed 
MANF (59). When they are injected into the brain tissues 
or when they are applied as recombinant proteins to the 
extracellular space they act through yet unknown recep-
tor. We know that for MANF the CXXC is important for in 
vivo neuroprotective effects, but not the last seven amino 
acids (ASARTDL) (59). CDNF was recently shown to be se-
creted at very low levels compared to MANF from ARPE-
19 cells (human retinal pigment epithelial cell line), and 
therefore that it was mainly in the cell, particularly at the ER 
(60). Interestingly, when the ER-retention signal of CDNF, 
KTEL, was deleted, secretion of CDNF was increased, simi-
larly to MANF as mentioned above. When CDNF was in-
jected into the striatum or cortex it readily diffused in the 
brain tissue and was taken up by neurons in an unspecif-
ic manner (24). Electron microscope studies showed that 
CDNF is found inside endosomes and multivesicular bod-
ies in the brain after recombinant protein injections, but 
how it mediates its neuroprotective effect needs further 
investigation. Overall, these findings could indicate differ-
ent mechanisms depending on if the proteins are applied 
to the cells or expressed in the cells themselves since it is 
not fully clear how they may exert their effects.
Evidence for different actions also comes from overexpres-
sion studies in cells and protein application in vivo. Cul-
tured neurons were protected when MANF was overex-
pressed, however not when it was applied exogenously 
(61). Indeed, MANF is drastically different from GDNF since 
the radiolabeled protein does not bind to the cell surface, 
indicating that it does not have a classical transmembrane 
receptor (61). Recently, it has been shown that the N-ter-
minus of MANF binds to sulphatides (62), and this may be 
how it is internalized after brain parenchymal injections, 
but this needs to be investigated further as well. Although 
CDNF has been neuroprotective when given to animals as 
a protein (in addition to overexpression via viral vector), 
this does not exclude the possibility that MANF could also 
be protective in this way. Also, there are other reports of 
MANF being applied to the culture medium and demon-
strating cell protection in non-neuronal cells (44). Perhaps, 
different cell types respond differently to extracellular vs 
intracellular MANF, and the brain as opposed to the in vit-
ro conditions are vastly different. The latter is unsurprising, 
however unfortunately we do not have enough evidence 
to precisely understand how these factors act at the cell 
surface to exert their protective effects.
What makes MANF interesting is that the chemically-in-
duced UPR increases intracellular MANF levels. Thus, it 
seems that MANF is able to bypass the translational block-
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age caused by the UPR, indicating that MANF is involved in 
coping with the increased levels of unfolded proteins in the 
ER lumen . Therefore, it may be speculated that similarly to 
the UPR, an endogenous protective and adaptive pathway 
for neurons, MANF expression increase is also part of an 
adaptive and protective pathway for cells. As mentioned 
above, thapsigargin, tunicamycin, or lactacystin, chemi-
cal inducers of the UPR. by blocking the SERCA pump, N-
linked glycolysation, or by inhibiting the proteasome, re-
spectively, all increase MANF levels in various cultured cells 
(63). Our study with the luciferase reporter shows that in 
cultured SH-SY5Y cells only thapsigargin and ER calcium 
depletion caused the secretion from cells, and tunicamy-
cin did not (56). Thus, from neurons or neuronal-like cells, 
MANF and CDNF secretion is not induced by all forms of 
ER stress, but by ER calcium depletion. For future studies it 
is interesting to investigate the physiological conditions in 
which ER calcium is depleted at a magnitude that causes 
exodosis (departure of ER resident proteins) (64-66).
CONCLUSIONS
CDNF and MANF have been shown to have therapeutic ef-
fects in various neurological disease models via administra-
tion of recombinant proteins or via the gene therapy ap-
proach. Their biology and mechanisms of neuroprotective 
effects have been challenging to study due to lack of re-
producible in vitro models. Whether the exogenously add-
ed neuroprotective effects are mediated similarly to protein 
functioning inside the ER lumen still needs to be addressed. 
The studies conducted so far are very intriguing from the 
point of view that the endogenous proteins expressed in 
the ER lumen show therapeutic effects when applied extra-
cellularly. In the future, it will be important to further study 
the therapeutic potential of ER resident proteins.
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